Ellen D Burgess

Summary

Affiliation: University of Calgary
Country: Canada

Publications

  1. pmc Consent for clinical research in the neonatal intensive care unit: a retrospective survey and a prospective study
    E Burgess
    Office of Medical Bioethics, Faculty of Medicine, University of Calgary, Calgary, AB, Canada
    Arch Dis Child Fetal Neonatal Ed 88:F280-5; discussion F285-6. 2003
  2. ncbi request reprint Long-term safety and efficacy of the selective aldosterone blocker eplerenone in patients with essential hypertension
    Ellen D Burgess
    Department of Medicine, University of Calgary, Calgary, Alberta, Canada
    Clin Ther 25:2388-404. 2003
  3. ncbi request reprint Losartan reduces the costs associated with nephropathy and end-stage renal disease from type 2 diabetes: Economic evaluation of the RENAAL study from a Canadian perspective
    Ellen D Burgess
    Department of Medicine, University of Calgary, Calgary, Alberta, Canada
    Can J Cardiol 20:613-8. 2004
  4. ncbi request reprint Eplerenone in hypertension
    Ellen Burgess
    University of Calgary, Department of Medicine, Faculty of Medicine, 2500 University Drive NW, Calgary, Alberta, T2N 1N4 Canada
    Expert Opin Pharmacother 5:2573-81. 2004
  5. pmc Supramaximal dose of candesartan in proteinuric renal disease
    Ellen Burgess
    Department of Medicine, University of Calgary, Calgary, Alberta
    J Am Soc Nephrol 20:893-900. 2009
  6. ncbi request reprint Effects of perindopril on elastic and structural properties of large arteries in essential hypertension
    Yves Lacourciere
    Centre hospitalier de l Universite Laval, Sainte Foy, Quebec
    Can J Cardiol 20:795-9. 2004
  7. ncbi request reprint A 26-week, prospective, open-label, uncontrolled, multicenter study to evaluate the effect of an escalating-dose regimen of trandolapril on change in blood pressure in treatment-naive and concurrently treated adult hypertensive subjects (TRAIL)
    Richard H Tytus
    Hamilton Health Sciences, Hamilton, Ontario, Canada
    Clin Ther 29:305-15. 2007

Detail Information

Publications7

  1. pmc Consent for clinical research in the neonatal intensive care unit: a retrospective survey and a prospective study
    E Burgess
    Office of Medical Bioethics, Faculty of Medicine, University of Calgary, Calgary, AB, Canada
    Arch Dis Child Fetal Neonatal Ed 88:F280-5; discussion F285-6. 2003
    ..Recruitment into research studies in the neonatal intensive care unit has been problematic. Therefore suggestions have been made to take decision making about enrollment out of the hands of the parents...
  2. ncbi request reprint Long-term safety and efficacy of the selective aldosterone blocker eplerenone in patients with essential hypertension
    Ellen D Burgess
    Department of Medicine, University of Calgary, Calgary, Alberta, Canada
    Clin Ther 25:2388-404. 2003
    ..Treatment with angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers does not sufficiently reduce plasma aldosterone levels...
  3. ncbi request reprint Losartan reduces the costs associated with nephropathy and end-stage renal disease from type 2 diabetes: Economic evaluation of the RENAAL study from a Canadian perspective
    Ellen D Burgess
    Department of Medicine, University of Calgary, Calgary, Alberta, Canada
    Can J Cardiol 20:613-8. 2004
    ..The Reduction of Endpoints in NIDDM [non-insulin-dependent diabetes mellitus] with the Angiotensin II Antagonist Losartan (RENAAL) study demonstrated the renoprotective effects of losartan in patients with nephropathy from type 2 diabetes...
  4. ncbi request reprint Eplerenone in hypertension
    Ellen Burgess
    University of Calgary, Department of Medicine, Faculty of Medicine, 2500 University Drive NW, Calgary, Alberta, T2N 1N4 Canada
    Expert Opin Pharmacother 5:2573-81. 2004
    ..Eplerenone is an effective, well-tolerated antihypertensive agent that may be used alone or in conjunction with other agents; apart from the risk of hyperkalaemia, adverse effects are similar to placebo...
  5. pmc Supramaximal dose of candesartan in proteinuric renal disease
    Ellen Burgess
    Department of Medicine, University of Calgary, Calgary, Alberta
    J Am Soc Nephrol 20:893-900. 2009
    ....
  6. ncbi request reprint Effects of perindopril on elastic and structural properties of large arteries in essential hypertension
    Yves Lacourciere
    Centre hospitalier de l Universite Laval, Sainte Foy, Quebec
    Can J Cardiol 20:795-9. 2004
    ..It decreases the stiffness of the larger arteries; questions remain as to the mechanisms involved and whether it is blood pressure (BP) control-dependent...
  7. ncbi request reprint A 26-week, prospective, open-label, uncontrolled, multicenter study to evaluate the effect of an escalating-dose regimen of trandolapril on change in blood pressure in treatment-naive and concurrently treated adult hypertensive subjects (TRAIL)
    Richard H Tytus
    Hamilton Health Sciences, Hamilton, Ontario, Canada
    Clin Ther 29:305-15. 2007
    ..This study evaluated the effectiveness of an escalating-dose regimen of trandolapril in subjects with stage 1 or stage 2 hypertension...